FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2806687972> ?p ?o ?g. }

• W2806687972 abstract "Objective: To compare alternative planned exploratory time-to-Nth seizure methodology with conventional primary efficacy analyses in children receiving pregabalin as adjunctive treatment for partial onset seizures (POS). Background: In conventional assessments of medication efficacy for POS, subjects remain on study drug or placebo for the entire treatment phase. Time-to-Nth seizure methodologies allow subjects to potentially exit earlier, while still providing evaluable efficacy endpoints. Design/Methods: The double-blind (DB), placebo-controlled, multi-country Study A0081041 (www.clinicialtrials.govNCT01389596) included an 8-week baseline phase (BL) and 12-week DB treatment phase (2-week dose escalation; 10-week fixed dose). Subjects (4–16 years old) with POS received stable regimens of 1–3 antiepileptic drugs. Treatments included pregabalin 2.5mg/kg/day (PGB-2.5; maximum 150mg/day), 10mg/kg/day (PGB-10; maximum 600mg/day), or placebo; doses were adjusted to achieve similar exposure for children weighing e (28-day seizure rates) over DB treatment, using linear mixed models with fixed-effect terms for baseline log e (28-day seizure rate), region, treatment, and weight. The alternative analysis was time-to-Nth seizure during DB treatment, where “Nth seizure” was derived from the 28-day BL seizure rate. Kaplan-Meier survival analysis and log-rank tests evaluated median time-to-Nth seizure and statistical significance, respectively. Results: 294 patients were analyzed (mean age 10.2 years, 55% male; PGB-10 n=97, PGB-2.5 n=104, placebo n=93). In the conventional approach, log e (28-day seizure rates) were reduced (relative to placebo) with PGB-10 (−19.9%, P =0.0185) and PGB-2.5 (−9.9%, P =0.2577). Using the alternative approach and censoring subjects not reaching Nth seizure, PGB-10 subjects reached their Nth seizure in the DB phase later than placebo ( P =0.0036). PGB-2.5 subjects showed a non-significant trend for longer time-to-Nth seizure versus placebo ( P =0.2721). Conclusions: Time-to-Nth seizure was longer for PGB-10 (significantly) and PGB-2.5 (numerically) versus placebo and compared favorably with the conventional analysis suggesting this as a viable trial methodology in pediatrics. Study Supported by: Pfizer Disclosure: Dr. Antinew has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer. Dr. Antinew has received compensation for serving on the Board of Directors of Pfizer. Dr. Knapp has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer. Dr. Knapp has received compensation for serving on the Board of Directors of Pfizer. Dr. Almas has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer. Dr. Liu has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer. Dr. Liu has received compensation for serving on the Board of Directors of Pfizer. Dr. Scavone has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer. Dr. Scavone has received compensation for serving on the Board of Directors of Pfizer. Dr. Parsons has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Pfizer. Dr. Parsons has received compensation for serving on the Board of Directors of Pfizer." @default.
• W2806687972 created "2018-06-13" @default.
• W2806687972 creator A5035847320 @default.
• W2806687972 creator A5040362413 @default.
• W2806687972 creator A5042073172 @default.
• W2806687972 creator A5042906464 @default.
• W2806687972 creator A5085068276 @default.
• W2806687972 creator A5085960628 @default.
• W2806687972 date "2018-04-10" @default.
• W2806687972 modified "2023-09-28" @default.
• W2806687972 title "Alternative Trial Methodology in Pediatric Epilepsy Clinical Trials - Time to “Nth” Seizure Analysis in Children with Partial Onset Seizures Treated With Pregabalin (S53.002)" @default.
• W2806687972 hasPublicationYear "2018" @default.
• W2806687972 type Work @default.
• W2806687972 sameAs 2806687972 @default.
• W2806687972 citedByCount "0" @default.
• W2806687972 crossrefType "journal-article" @default.
• W2806687972 hasAuthorship W2806687972A5035847320 @default.
• W2806687972 hasAuthorship W2806687972A5040362413 @default.
• W2806687972 hasAuthorship W2806687972A5042073172 @default.
• W2806687972 hasAuthorship W2806687972A5042906464 @default.
• W2806687972 hasAuthorship W2806687972A5085068276 @default.
• W2806687972 hasAuthorship W2806687972A5085960628 @default.
• W2806687972 hasConcept C118552586 @default.
• W2806687972 hasConcept C126322002 @default.
• W2806687972 hasConcept C142724271 @default.
• W2806687972 hasConcept C187212893 @default.
• W2806687972 hasConcept C204787440 @default.
• W2806687972 hasConcept C27081682 @default.
• W2806687972 hasConcept C2776468701 @default.
• W2806687972 hasConcept C2777803345 @default.
• W2806687972 hasConcept C2778186239 @default.
• W2806687972 hasConcept C42219234 @default.
• W2806687972 hasConcept C65409693 @default.
• W2806687972 hasConcept C71924100 @default.
• W2806687972 hasConceptScore W2806687972C118552586 @default.
• W2806687972 hasConceptScore W2806687972C126322002 @default.
• W2806687972 hasConceptScore W2806687972C142724271 @default.
• W2806687972 hasConceptScore W2806687972C187212893 @default.
• W2806687972 hasConceptScore W2806687972C204787440 @default.
• W2806687972 hasConceptScore W2806687972C27081682 @default.
• W2806687972 hasConceptScore W2806687972C2776468701 @default.
• W2806687972 hasConceptScore W2806687972C2777803345 @default.
• W2806687972 hasConceptScore W2806687972C2778186239 @default.
• W2806687972 hasConceptScore W2806687972C42219234 @default.
• W2806687972 hasConceptScore W2806687972C65409693 @default.
• W2806687972 hasConceptScore W2806687972C71924100 @default.
• W2806687972 hasLocation W28066879721 @default.
• W2806687972 hasOpenAccess W2806687972 @default.
• W2806687972 hasPrimaryLocation W28066879721 @default.
• W2806687972 hasRelatedWork W1555860353 @default.
• W2806687972 hasRelatedWork W1565997261 @default.
• W2806687972 hasRelatedWork W1783257732 @default.
• W2806687972 hasRelatedWork W2758399883 @default.
• W2806687972 hasRelatedWork W2803952614 @default.
• W2806687972 hasRelatedWork W2805066472 @default.
• W2806687972 hasRelatedWork W2806435685 @default.
• W2806687972 hasRelatedWork W2808055426 @default.
• W2806687972 hasRelatedWork W2809418345 @default.
• W2806687972 hasRelatedWork W2809523820 @default.
• W2806687972 hasRelatedWork W2809684180 @default.
• W2806687972 hasRelatedWork W2883358571 @default.
• W2806687972 hasRelatedWork W2885430857 @default.
• W2806687972 hasRelatedWork W2886259731 @default.
• W2806687972 hasRelatedWork W2888596619 @default.
• W2806687972 hasRelatedWork W2898365980 @default.
• W2806687972 hasRelatedWork W2921858277 @default.
• W2806687972 hasRelatedWork W2976572331 @default.
• W2806687972 hasRelatedWork W3157748139 @default.
• W2806687972 hasRelatedWork W2809596465 @default.
• W2806687972 hasVolume "90" @default.
• W2806687972 isParatext "false" @default.
• W2806687972 isRetracted "false" @default.
• W2806687972 magId "2806687972" @default.
• W2806687972 workType "article" @default.